Kolon Life Science Inc. (KOSDAQ:102940)

South Korea flag South Korea · Delayed Price · Currency is KRW
63,800
-1,200 (-1.85%)
At close: Feb 27, 2026
138.06%
Market Cap 833.41B
Revenue (ttm) 211.13B
Net Income (ttm) 17.80B
Shares Out 13.06M
EPS (ttm) 1,290.73
PE Ratio 49.43
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 53,616
Average Volume 60,538
Open 66,100
Previous Close 65,000
Day's Range 63,000 - 66,400
52-Week Range 23,500 - 72,700
Beta 0.06
RSI 58.34
Earnings Date Mar 19, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ... [Read more]

Industry Chemicals
Sector Materials
Founded 2000
Employees 426
Stock Exchange KOSDAQ
Ticker Symbol 102940
Full Company Profile

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.

Financial Statements

News

There is no news available yet.